GLP 1 Agonists

This hub provides a comprehensive overview of GLP-1 receptor agonists, semaglutide, and related peptide therapeutics, integrating the latest scientific evidence and clinical perspectives. The linked articles examine the mechanisms of GLP-1–based therapies in weight loss, diabetes management, and beyond, as well as their emerging roles in addressing conditions such as alcohol addiction and menopause-related metabolic changes. Readers will find detailed discussions on efficacy, safety, patient selection, and the comparative potential of novel molecules like berberine. The collection also explores broader trends in peptide therapeutics and the future landscape of targeted treatment. This resource is designed for healthcare professionals, researchers, and individuals seeking authoritative, evidence-based information on GLP-1 and peptide-based interventions.

How Oral GLP-1 Drugs Work For Weight Loss

Discover how next-generation oral GLP-1 therapies are transforming weight management by breaking through the stomach’s toughest barriers and opening the door to powerful, needle-free metabolic treatments.

Overview

Explore authoritative articles on GLP-1, semaglutide, peptide therapeutics, weight loss, diabetes, and emerging treatments. This hub delivers evidence-based insights for clinicians, researchers, and anyone interested in targeted therapies.

Is Berberine Really “Nature’s Ozempic”? What Science Says

Wegovy: A Breakthrough in Weight Loss?

Who Should Take Weight Loss Injections, and Who Shouldn’t?

Gut-Brain Axis and Obesity

The Potential of Peptide Therapeutics in Treating Chronic Diseases

Oral GLP-1 Pills for Weight Loss: How Orforglipron Works

Are GLP-1 Drugs the Future of Alcohol Addiction Treatment?

Top Nutrients and Habits That Boost GLP-1 Naturally

Multiple Endocrine Neoplasia Type 1 (MEN1)

Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes

What Are Advanced Glycation End Products and Why They Matter

See more featured articles »

The Future of Diabetes Treatment

The Unexpected Effects of GLP-1 Medications on Women’s Health

The Impact of Glucagon on Diabetes Management

Semaglutide and Weight Loss in Menopause

The Natural Molecule That Could Rival Ozempic

How Does Semaglutide Work to Lose Weight?

Recent Advancements in Treatment for Parkinson’s Disease

GLP-1 and Diet: Evidence-Based Strategies for Better Weight Loss

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Peptide Therapy: The Future of Targeted Treatment?

Latest GLP 1 Agonists News and Research

Bariatric surgery reshapes body fat and muscle more than GLP-1 drugs

Bariatric surgery and GLP-1 treatments reshape body composition differently, emphasizing the importance of sex and treatment choice in muscle preservation.

14 Jan 2026

Most patients regain lost weight within two years of stopping obesity drugs

Weight management medications show limited long-term effects, with rapid weight regain post-treatment, emphasizing the need for sustainable obesity strategies.

13 Jan 2026

Why adherence determines weight loss success with semaglutide

Researchers examine how the effectiveness of weight-loss medications may depend on the patient adherence.

12 Jan 2026

Weight loss drugs and surgery improve body composition in patients with obesity

Both the new weight loss drugs and bariatric (weight loss) surgery improve body composition in patients with obesity by inducing a moderate loss of fat-free mass (including lean muscle) along with a substantial reduction in fat, researchers at Vanderbilt Health have found.

9 Jan 2026

Study highlights prevalence of GLP-1/GIP medication use for weight loss in UK

In early 2025, around 4.9 million British adults - almost one in ten - are estimated to have recently used, or expressed interest in using, glucagon-like peptide-1 (GLP-1) or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist medications to support weight loss. The findings, which are based on a nationally representative household survey of 5,260 British adults, are published in BMC Medicine.

8 Jan 2026

Weight loss drugs may cause nutritional deficiencies without proper guidance

People prescribed the new generation of weight loss drugs may not receive sufficient nutritional guidance to support safe and sustainable weight loss, leaving them vulnerable to nutritional deficiencies and muscle loss, say experts at UCL and the University of Cambridge.

7 Jan 2026

Millions in Great Britain using or seeking weight loss drugs

An estimated 1.6 million adults in England, Wales and Scotland used drugs such as Wegovy and Mounjaro to help lose weight between early 2024 and early 2025, according to a new study by UCL (University College London) researchers.

7 Jan 2026

Stopping weight loss drugs leads to rapid weight regain and health reversal

Stopping weight loss drugs is followed by weight regain and reversal of beneficial effects on heart and metabolic health markers such as high cholesterol and high blood pressure, finds a study published by The BMJ today.

7 Jan 2026

How GLP‑1 agonists are shaping the future of obesity treatment with Dr Bryony Henderson

GLP-1 agonists are pivotal in obesity care, promoting weight loss and addressing related health issues, with a focus on personalized, holistic treatment.

23 Dec 2025

Fatty diets reprogram hepatocytes and increase liver cancer risk

One of the biggest risk factors for developing liver cancer is a high-fat diet. A new study from MIT reveals how a fatty diet rewires liver cells and makes them more prone to becoming cancerous.

22 Dec 2025

Glucose-lowering drugs may reduce risk of developing epilepsy

A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The study was published on December 10, 2025, in Neurology, the medical journal of the American Academy of Neurology.

10 Dec 2025

Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study

Researchers profiled a terminally sterilized probiotic-fermented MFH beverage and identified aporphine alkaloids and flavonoids with favorable predicted ADMET properties. Integrated network pharmacology, molecular docking, and 100-ns MD simulations suggest multi-target engagement of metabolic-inflammatory pathways relevant to obesity and type 2 diabetes.

9 Dec 2025

Sudden cardiac death risk is sharply elevated in people with diabetes

The risk of sudden cardiac death is higher both for people with type 1 and type 2 diabetes, according to a large study published in the European Heart Journal today (Thursday). The increase in risk is especially noticeable among younger adults.

3 Dec 2025

Diabetes drugs linked to slower frailty progression in older adults

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors-such as empagliflozin (Jardiance) and dapagliflozin (Farxiga)-or glucagon-like peptide-1 (GLP-1) receptor agonists-such as semaglutide (Ozempic) and liraglutide (Victoza)-experience slower progression of frailty over one year compared with those starting other diabetes medications.

3 Dec 2025

Obesity-driven estrone emerges as a key driver of deadly postmenopausal breast cancer

A new analysis of research into the most common type of breast cancer has zeroed in on an overlooked hormone that may be responsible for the increased risk of breast cancer death in post-menopausal women with obesity.

2 Dec 2025

WHO releases first guideline on the use of GLP-1 therapies for treating obesity

To address the growing global health challenge of obesity, which affects more than 1 billion people, the World Health Organization (WHO) has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease.

2 Dec 2025